San Clemente, Calif.-based Glaukos Corp. reported 22% net sales growth to $65.8 million in the final quarter of 2019, up from $54.1 million in the same period a year ago. However, it also warned that increasing competition in the microinvasive glaucoma surgery (MIGS) space could dampen 2020 growth in its U.S. glaucoma business. Speaking with analysts on a fourth-quarter earnings call, CEO Thomas Burns said good conversion rates and growing surgeon interest in its next-generation trabecular bypass device, Istent Inject, may not be enough to counter the headwind.
Keeping you up to date on recent developments in diagnostics, including: Chest CT bests assays in diagnosing Covid-19; Sweat sensor keeps tabs on stress; Oligodendrocyte-neural connections not just about myelin; Sharper look yields new potential kinase target in ovarian cancer.
London-based Livanova plc has entered a collaboration with Verily Inc., an Alphabet company, to enrich data from its RECOVER trial using tools and analytics developed by Verily. The study, which kicked off last September, is assessing the effectiveness of vagus nerve stimulation (VNS) therapy for patients with difficult-to-treat depression (DTD).
Waveguide Corp. has launched the first portable, battery-powered nuclear magnetic resonance (NMR) device, Waveguide Formμla, offering rapid, on-site screening and diagnostics. The Cambridge, Mass.-based startup is looking to advance the product for use in detecting infectious diseases and cancer.
NATIONAL HARBOR, Md. – Berlin-based Biotronik SE & Co. reported new data from the BIOFLOW-V trial showing that its Orsiro ultrathin strut drug-eluting stent (DES) continued to outperform Abbott Laboratories’ Xience DES through three years’ follow-up.
NATIONAL HARBOR, Md. – Cardiovalve Ltd., of Or Yehuda, Israel, scored a double hit with the U.S. FDA, winning a breakthrough device designation for its transcatheter tricuspid valve replacement system, as well as approval to conduct an early feasibility study in tricuspid regurgitation (TR).
Keeping you up to date on recent developments in diagnostics, including: Detailed mapping of breast tumors sheds light on role of genetic variations; Leveraging AI in breast cancer diagnosis; T cell population is biomarker for β-cell function; Oligodendrocyte-neural connections not just about myelin.
Medical device companies are seeking to reduce product defects and increase patient safety with an industry-managed program that focuses on final product quality via oversight of the most critical manufacturing processes. Modeled on a 30-year-old aerospace industry program called Nadcap, Medaccred brings device manufacturers and suppliers together to define accreditation for special processes.
Cambridge, Mass., startup Enclear Therapies Inc. has secured $10 million in series A financing led by 20/20 Healthcare Partners. The company is developing a device to aid in treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid (CSF).
Medtronic plc, of Dublin, blamed dampened demand for heart devices ahead of new product launches for its third-quarter revenue miss. Fiscal 2020 Q3 revenue totaled $7.72 billion, below Wall Street’s estimate of $7.81 billion, for organic sales growth of 2.6% vs. consensus and guidance of 4% or higher.